You are here: Home » PTI Stories » National » News
Business Standard

Laurus Labs-Aspen Pharmacare launch HIV drug in South Africa

Press Trust of India  |  Hyderabad 

Laurus Labs, a city-based pharma company Sunday said it has launched a new drug with the triple combination of Fumarate, and (TLD) in

According to a press release from the Indian drug maker, the was launched on November 26 in collaboration with Aspen Pharmacare, a South African company.

Earlier, Aspen Pharma, received approvals for the dossier where Aspen and Laurus Labs, are registered as manufacturing facilities, from the South African Health Products Regulatory Authority (SAHPRA).

The product provides significant benefits to existing therapies, including countering drug resistance that often develops with older treatments.

This once-a-day triple combination tablet is positioned to become a preferred first-line ARV choice in multiple markets.

It would be available in 50mg/300mg/300mg dosages, it said.

As part of the partnership, Aspen launched the product in for the private market and would supply the API, from its located in Jawaharlal Nehru Pharmacity, Visakhapatnam,

This state-of-the-art facility is approved by USFDA, the release said.

Founder and of Laurus Labs, Satyanarayana Chava said, "We are happy to contribute to the treatment of millions of patients across the globe through our fully integrated and the state-of-the-art

I am sure that the new triple combination drug will contribute to the successful treatment of patients affected by HIV and

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Sun, December 02 2018. 18:10 IST